RxSight (RXST) Stock Forecast: StockMap's 2-Week Call
RXST stock forecast: StockMap's model makes no two-week call on RxSight after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 3 of 6 two-week windows on RXST since Aug 21; by chance, a call on the same dates was right 58% of the time.
RxSight last closed at $4.61, -7.98% on the session.
Against the IVW growth benchmark the position is -5.65% over the forecast window.
RxSight's market cap is $193.30M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 1 (too close to call).
Where RXST sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 33%.
45 daily calls for RXST so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks RxSight in the 27th percentile on return on equity, where 100 is best.
RxSight is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks RxSight as the 93rd largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.
On that composite RxSight ranks 27th of 141 in the group, against a group median of -0.18.